Safety of Factor XI Inhibition With Abelacimab in Atrial Fibrillation by Kidney Function
In this secondary analysis of the AZALEA-TIMI 71 randomized clinical trial, abelacimab consistently reduced the risk of bleeding relative to rivaroxaban irrespective of kidney function. These findings suggest that abelacimab may offer a particularly favorable safety profile among those with chronic kidney disease; however, larger studies are necessary to characterize the efficacy of abelacimab for stroke prevention in AF.
Authors
- Róbert Gábor Kiss (ORCID: https://orcid.org/0000-0003-0514-7530)
- Christian T. Ruff (ORCID: https://orcid.org/0000-0002-4712-3206)
- Wojciech Wojakowski (ORCID: https://orcid.org/0000-0002-3681-5207)
- Erica L. Goodrich (ORCID: https://orcid.org/0000-0002-8541-264X)
- Marc S. Sabatine (ORCID: https://orcid.org/0000-0002-0691-3359)
- Robert P. Giugliano (ORCID: https://orcid.org/0000-0003-4110-7675)
- Boyoung Joung (ORCID: https://orcid.org/0000-0001-9036-7225)
- Siddharth M. Patel (ORCID: https://orcid.org/0000-0002-4637-4361)
- Bruce A. Hug (ORCID: https://orcid.org/0000-0003-1726-5198)
- Sanobar Parkar
- Dan Bloomfield
- Andrew W. Murphy (ORCID: https://orcid.org/0000-0001-5549-8246)
- David A. Morrow
- Shih-Ann Chen
- Jeffrey I. Weitz
- Shaun G. Goodman
Institutions
- Semmelweis University (HU)
- Brigham and Women's Hospital (US)
- St. Michael's Hospital (CA)
- Harvard University (US)
- University of Alberta (CA)
- Medical University of Silesia (PL)
- Yonsei University (KR)
- Severance Hospital (KR)
- Taipei Veterans General Hospital (TW)
- DecImmune Therapeutics (United States) (US)
- Canadian VIGOUR Centre (CA)
- Sarepta Therapeutics (United States) (US)
- Thrombosis and Atherosclerosis Research Institute (CA)
- Thrombolysis in Myocardial Infarction Study Group (US)
- McMaster University (CA)
Publication Details
- Journal
- JAMA Cardiology
- Published
- 2025-09-01
- DOI
- https://doi.org/10.1001/jamacardio.2025.3393
- Primary Topic
- Coagulation, Bradykinin, Polyphosphates, and Angioedema
- Type
- article
- Field-Weighted Citation Impact
- 0.00